Impact of T315I Mutation on Chronic Myeloid Leukemia Prognosis
Author Information
Author(s): Kaleem Bushra, Shahab Sadaf, Shamsi Tahir Sultan
Primary Institution: National Institute of Blood Disease and Bone Marrow Transplantation, Karachi, Pakistan
Hypothesis
The study aimed to observe the frequency of T315I mutation and its impact on disease prognosis in chronic myeloid leukemia.
Conclusion
Early identification of the T315I mutation can help redirect treatment for chronic myeloid leukemia patients.
Supporting Evidence
- T315I mutation was detected in 21.6% of non-responder patients.
- Overall survival in patients with T315I mutation was 81.8% over 96 months.
- 58.8% of mutation-harbouring patients progressed to the blastic phase.
Takeaway
Some people with chronic myeloid leukemia have a mutation called T315I that makes their treatment less effective, and finding this mutation early can help doctors choose better treatments.
Methodology
Patients labeled as non-responders to TKI treatment were assessed for T315I mutation using ARMS-PCR and followed for 96 months.
Limitations
The study could not monitor cytogenetic and molecular responses at pre-determined landmarks.
Participant Demographics
The median age of mutation-harbouring patients was 37.5 years, with a female predominance of 54.5%.
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website